Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4146349 | 0.91 | MAPK14 (0.44) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL18546331 | 0.84 | MAPK14 (0.53) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL14300702 | 0.82 | GRN (0.49) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL17436793 | 0.82 | GRN (0.49) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL2243158 | 0.81 | MAPK13 (0.54) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL16910281 | 0.78 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL4078830 | 0.76 | CDK8 (0.59) | MAPK14MAPK13MAPK12MAPK11RECQL | |
| SCHEMBL17436792 | 0.75 | GRN (0.43) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL981097 | 0.75 | MAPK14 (0.39) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL4497925 | 0.74 | MAPK14 (0.48) | GRNSORT1MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076356-B2 | Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors | PFIZER INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | GRN 1671/4885SORT1 3643/4885MAPK14 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.